3-(Methoxymethyl)-4-(2-methylpiperidin-1-yl)benzoic acid → Ethyl 4-(2-fluoro-4-{5-[3-(methoxymethyl)-4-(2-methylpiperidin-1-yl)phenyl]-1,2,4-oxadiazol-3-yl}phenoxy)butanoate

참여 물질

반응 단계

The title compound was prepared following procedure described for example 141, step 1, but starting from Intermediate 58 (158 mg; 0.60 mmol) and Intermediate 66 (162.04 mg; 0.57 mmol), the crude mixture was purified by flash chromatography (c-hex/(DCM/EtOAc 1:1) gradient from 1:0 to 1:1) to afford the title compound as a colorless oil. 1H NMR (CDCl3) δ 8.30 (d, J=2.1 Hz, 1H), 8.07 (dd, J=8.2, 2.0 Hz, 1H), 7.92-7.87 (m, 2H), 7.26 (d, J=8.4 Hz, 1H), 7.06 (t, J=8.5 Hz, 1H), 4.67-4.61 (m, 2H), 4.20-4.13 (m, 4H), 3.49 (s, 3H), 3.17 (br s, 1H), 3.06-3.03 (m, 1H), 2.65 (br s, 1H), 2.57 (t, J=7.3 Hz, 2H), 2.19 (quint, J=6.6 Hz, 2H), 1.86-1.70 (m, 4H), 1.51-1.48 (m, 2H), 1.27 (t, J=7.1 Hz, 3H), 0.90 (d, J=6.0 Hz, 3H). LC/MS (Method B): 512.4 (M+H)+. HPLC (Method A) Rt 4.62 min (Purity: 100.0%).

출처 및 근거